MYHEP

This brand name is authorized in Nigeria. It is also authorized in Tunisia.

Active ingredients

The drug MYHEP contains one active pharmaceutical ingredient (API):

1	Sofosbuvir UNII WJ6CA3ZU8B - SOFOSBUVIR
	Sofosbuvir is a pan-genotypic inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.
	Read more about Sofosbuvir

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-8329	Tablet	MyHep Tablets TAB 400 mg 1 x 28's	Film-coated tablets MYHEP TABLETS SOFOSBUVIR 400MG Sofosbuvir 400mg.Inactive Ingredients: Mannitol 360mg,Microcrystalline Cellulose 356mg, Croscarmellose Sodium 60mg, Colloidal Silicon Dioxide 6mg, Magnesium Stearate 18 mg, Opadry II Orange 36mg, Purified Water B4-8329 Drugs ANTIINFECTIVES FOR SYSTEMIC USE Imported Products 128 Prescription Only Medicine (POM) 22/04/2024 HEALTHLINE LIMITED, 29,ADENIYI JONES IKEJA LAGOS 7081123545 healthline.ng@gmail.com Mylan Laboratories Limited (Nashik), F-4 & F-12 MIDC, Malegaon, Sinnar, Nashik - 422 113, Maharashtra, India, India	30/01/2025

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AP08		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AP Antivirals for treatment of HCV infections
Discover more medicines within J05AP08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-8329
TN	Direction de la Pharmacie et du Médicament	17443011H